Equinoxe 假体初次解剖与反式全肩关节置换翻修风险比较
基于美国医疗系统肩关节置换登记数据,纳入 13,901 例成人初次择期解剖全肩(ATSA)、择期反式全肩(RTSA)或骨折后 RTSA 患者(2005–2023),采用多变量 Cox 回归比较 Equinoxe 与其他假体的全因翻修风险。调整分析显示 Equinoxe ATSA 翻修风险更高(HR=1.87,95%CI 1.33–2.62),择期 RTSA 与骨折 RTSA 未见差异。
要点
- Equinoxe 解剖全肩翻修风险高于其他假体(HR=1.87,95%CI 1.33–2.62)。
- 仅限非合规包装 Equinoxe 解剖全肩亚组分析亦显示翻修风险升高(HR=1.91,95%CI 1.34–2.72)。
- 择期反式全肩与骨折反式全肩中 Equinoxe 与其他假体翻修风险未见差异。
核心结论
- Equinoxe 假体用于解剖全肩关节置换时全因翻修风险高于其他假体。
- Equinoxe 假体用于择期反式全肩或骨折反式全肩时,翻修风险与其他假体未见差异。
研究设计与样本
- 美国医疗系统肩关节置换登记数据的队列研究,纳入 13,901 例成人初次择期 ATSA、择期 RTSA 或骨折 RTSA 患者(2005–2023)。
- ATSA 队列 N=8,707,平均年龄 68 岁,男性 53.3%,白人 84.7%。
- 择期 RTSA 队列 N=4,374,平均年龄 74 岁,男性 41.2%,白人 79.9%。
- 骨折 RTSA 队列 N=820,平均年龄 73 岁,男性 16.3%,白人 78.4%。
- 采用多变量 Cox 回归进行协变量调整,评估 Equinoxe 与其他假体的全因翻修风险。
主要发现
- 调整分析中,Equinoxe ATSA 相较其他假体翻修风险更高(HR=1.87,95%CI 1.33–2.62)。
- 仅限非合规包装 Equinoxe ATSA 的亚组分析亦显示翻修风险更高(HR=1.91,95%CI 1.34–2.72)。
- 择期 RTSA 中 Equinoxe 与其他假体翻修风险未见差异(HR=0.71,95%CI 0.33–1.49)。
- 骨折 RTSA 中 Equinoxe 与其他假体翻修风险未见差异(HR=2.30,95%CI 0.84–6.28)。
关键数值与推荐
- 2024 年 Exactech 因部分 Equinoxe 假体包装袋缺少乙烯-乙烯醇共聚物二次氧气阻隔层而不合规,实施自愿召回。
- 证据等级为治疗性 III 级。
临床怎么用
- 对曾接受 Equinoxe 解剖全肩关节置换的患者,临床应关注其翻修风险可能升高。
- Equinoxe 用于择期反式全肩或骨折反式全肩时,翻修风险与其他假体未见差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2024, Exactech issued a voluntary recall of Equinoxe devices after finding that some devices had been packaged in bags that were non-conforming because a secondary oxygen barrier layer of ethylene vinyl alcohol was missing. We sought to evaluate the revision risk following shoulder arthroplasty using an Exactech Equinoxe device compared with other eligible devices. METHODS: We conducted a cohort study using data from a U.S. health-care system's shoulder arthroplasty registry. The study included 13,901 adult patients who had undergone primary elective anatomic total shoulder arthroplasty (ATSA), elective reverse total shoulder arthroplasty (RTSA), or RTSA for fracture (2005 to 2023). The mean age for the ATSA cohort (N = 8,707) was 68 years, 53.3% were male, and 84.7% were White. Corresponding values for the elective RTSA cohort (N = 4,374) were 74 years, 41.2% male, and 79.9% White, and those for the RTSA for fracture cohort (N = 820) were 73 years, 16.3% male, and 78.4% White. Multivariable Cox regression with covariate adjustment was used to evaluate all-cause revision risk for Equinoxe devices compared with other devices. RESULTS: In adjusted analyses, a higher revision risk was observed for ATSAs with Equinoxe versus other devices (hazard ratio [HR] = 1.87, 95% confidence interval [CI] = 1.33 to 2.62). The higher revision risk was also observed in a subanalysis restricted to ATSAs with Equinoxe devices packaged in non-conforming bags (HR = 1.91, 95% CI = 1.34 to 2.72). No differences were observed in elective RTSAs (HR = 0.71, 95% CI = 0.33 to 1.49) or RTSAs for fracture (HR = 2.30, 95% CI = 0.84 to 6.28) with Equinoxe compared with other devices. CONCLUSIONS: We observed a higher revision risk with the use of Equinoxe devices in ATSA, but no difference for Equinoxe devices in elective RTSA compared with other devices. While all Equinoxe devices packaged in non-conforming bags were recalled worldwide in 2024, clinicians should be mindful of these findings when a patient had previously received an Equinoxe ATSA device. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Prentice HA, Chang RN, Yian E, et al. Revision Risk Following Primary Anatomic and Reverse TSA with an Exactech Equinoxe Compared with Other Devices: A U.S.-Based Cohort Study. J Bone Joint Surg Am. 2026. PMID: 42743297. doi:10.2106/JBJS.25.01594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。